Sign In
Buy FMS
$25.66
-0.0400 (-0.156%)
At Close: Jul 31, 2026
Yousif Capital Management LLC Increases Stock Holdings in Fresenius Medical Care AG & Co. KGaA $FMS
03:48am, Friday, 24'th Oct 2025
Yousif Capital Management LLC lifted its holdings in shares of Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) by 6.8% during the undefined quarter, according to its most recent disclosure with the
Here's Why Fresenius (FMS) is a Strong Value Stock
10:40am, Thursday, 16'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FMS vs. OFIX: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 07'th Oct 2025
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Orthofix (OFIX). But which of these two stocks offers value investors a better bang fo
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 02'nd Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
09:35am, Wednesday, 01'st Oct 2025
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hof
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 24'th Sep 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
02:16pm, Tuesday, 23'rd Sep 2025
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set d
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical
Focus Graphite Advanced Materials Announces Closing of C$891,000 Non-Brokered Private Placement
06:19pm, Friday, 08'th Aug 2025
Ottawa, Ontario--(Newsfile Corp. - August 8, 2025) - Focus Graphite Advanced Materials Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), is pleased to announce it has closed a no
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 07'th Aug 2025
Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity ri
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
11:41am, Wednesday, 06'th Aug 2025
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
11:23am, Tuesday, 05'th Aug 2025
Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger -
Silicon Motion Showcases MonTitan™ SM8366 in Core to Edge AI Server Applications at FMS 2025
09:00am, Tuesday, 05'th Aug 2025
Company Also Demonstrates Full Spectrum of AI Storage Solutions for PCs, Gaming, Edge, Robotics, and Automotive TAIPEI and MILPITAS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Silicon Motion Technology Co
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025
07:00am, Tuesday, 05'th Aug 2025
Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed t
